Summary

The Clot Management Devices Market was valued for $2,097.32 million in 2023 and is estimated to reach $4,310.20 million by 2035, exhibiting a CAGR of 6.2% from 2024 to 2035.
Clot management devices are medical tools designed to address blood clots that form in veins and arteries, which often lead to serious conditions such as deep vein thrombosis (DVT), pulmonary embolism, stroke, and peripheral arterial disease. These devices help to either dissolve or remove clots, restoring proper blood flow and preventing complications such as tissue damage or organ failure. Clot management devices are used in various medical settings, including interventional radiology, cardiology, and neurology. They play a critical role in emergency treatment for strokes, in managing chronic conditions such as deep vein thrombosis, and in preventing further complications in patients at high risk for clot formation.

Major factors driving the growth of clot management devices market are surge in prevalence of cardiovascular diseases, technological advancement in the clot management devices, and development in healthcare infrastructure especially in middle income countries. The rise in prevalence of cardiovascular diseases is a major driver for the clot management devices market expansion, as these conditions significantly increase the risk of blood clot formation. Cardiovascular diseases, such as coronary artery disease, atrial fibrillation, and peripheral artery disease, often lead to complications such as deep vein thrombosis, pulmonary embolism, and stroke, all of which require effective clot management solutions. According to a 2021 article by the National Library of Medicine, coronary artery disease alone accounts for 15.5% of total deaths globally, highlighting the substantial burden of these conditions. As the incidence of cardiovascular diseases rises, driven by factors such as unhealthy lifestyles, aging populations, and increased prevalence of risk factors such as hypertension and diabetes, the demand for clot management devices continues to grow. These devices play a critical role in preventing and treating life-threatening blood clots, driving their increased adoption in clinical settings.

Furthermore, technological advancements in clot management boost the growth of the market, as they enable more precise, effective, and less invasive treatments for blood clots. Innovative devices designed for faster clot removal and enhanced patient safety have transformed the management of conditions such as deep vein thrombosis and pulmonary embolism. A notable example is the Cleaner Vac Thrombectomy System, launched by Argon Medical Devices in September 2024. This system is a disposable, large-bore aspiration device specifically designed to remove blood clots quickly and effectively, or thrombus, from the peripheral venous vasculature. The Cleaner Vac empowers physicians with manual control overpowered aspiration, allowing for precise clot removal while minimizing the risk of vessel damage and reducing blood loss. Such advancements improve procedural efficiency and enhance patient outcomes by reducing complications and recovery times.

The continuous introduction of technologically advanced devices such as the Cleaner Vac is driving increased adoption of clot management devices in hospitals and clinics, further fueling market growth. Moreover, the development of healthcare infrastructure in middle-income countries is a crucial driver of the growth of the clot management devices market, as it significantly enhances the capacity to diagnose and treat cardiovascular diseases & thrombotic conditions. As these countries continue to improve their healthcare systems, the demand for advanced medical technologies rises, including clot management devices. According to a 2024 article by the Press Information Bureau, Government Health Expenditure accounted for around 1.84% of the GDP of India. This substantial investment enables the expansion of healthcare facilities, including specialized hospitals and clinics that are better equipped to handle complex medical conditions.

The clot management devices market is segmented on the basis of product, end user, and region. By product, the market is classified into neurovascular embolectomy devices, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (CDT) devices, and inferior vena cava filters (IVCF). By end user, it is segregated into hospitals and other end user. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the market include Boston Scientific Corporation, Edwards Lifesciences Corporation, Medtronic plc, Johnson & Johnson, Abbott Laboratories, AngioDynamics, Inc., Stryker Corporation, Terumo Corporation, Penumbra, Inc., and Koninklijke Philips N.V.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the clot management devices market analysis from 2023 to 2035 to identify the prevailing clot management devices market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the clot management devices market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global clot management devices market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By Product
● Neurovascular Embolectomy Devices
● Embolectomy Balloon Catheters
● Percutaneous Thrombectomy Devices
○ Type
○ Mechanical Thrombectomy
◦ Type
○ Aspiration Thrombectomy
◦ Type
● Catheter-Directed Thrombolysis Devices
● Inferior Vena Cava Filters
○ Type
○ Permanent
○ Retrieval
By End User
● Hospitals
● Other End Users
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Abbott Laboratories
○ AngioDynamics, Inc.
○ Boston Scientific Corporation
○ Edwards Lifesciences Corporation
○ Johnson and Johnson
○ Koninklijke Philips N.V.
○ Medtronic plc
○ Penumbra, Inc.
○ Stryker Corporation
○ Terumo Corporation

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of thromboembolic disorders
3.4.1.2. Developing healthcare infrastructure
3.4.1.3. Growing trend towards minimally invasive surgeries
3.4.2. Restraints
3.4.2.1. High cost of clot management devices
3.4.3. Opportunities
3.4.3.1. Technological advancement in the clot management devices
CHAPTER 4: CLOT MANAGEMENT DEVICES MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Neurovascular Embolectomy Devices
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Embolectomy Balloon Catheters
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Percutaneous Thrombectomy Devices
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.4.4. Percutaneous Thrombectomy Devices Clot Management Devices Market by Type
4.4.4.1. Mechanical Thrombectomy Clot Management Devices Market by Type
4.4.4.2. Aspiration Thrombectomy Clot Management Devices Market by Type
4.5. Catheter-Directed Thrombolysis Devices
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Inferior Vena Cava Filters
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.6.4. Inferior Vena Cava Filters Clot Management Devices Market by Type
CHAPTER 5: CLOT MANAGEMENT DEVICES MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Other End Users
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: CLOT MANAGEMENT DEVICES MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Product
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Product
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Product
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Product
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Product
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Product
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Product
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Product
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Product
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Product
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Product
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Product
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Product
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Product
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Product
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Product
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Product
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Product
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Product
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Product
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Product
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Product
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Product
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Boston Scientific Corporation
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Edwards Lifesciences Corporation
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Medtronic plc
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Johnson and Johnson
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Abbott Laboratories
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. AngioDynamics, Inc.
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Stryker Corporation
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.8. Terumo Corporation
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Penumbra, Inc.
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Koninklijke Philips N.V.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance